Chapter fifteen - Chitosan-Coated Solid Lipid Nanoparticles for Insulin Delivery
Introduction
Insulin has been usually administered subcutaneously for the treatment of diabetes mellitus. Several attempts have been made to find alternative routes of insulin administration that improve patient compliance and avoid injections (Cefalu, 2004, Ghilzai, 2003, Owens, 2002). Among all routes, oral delivery is the most desirable one since it is noninvasive thus avoiding the contamination/infection risks associated with injectables, and is physiologically advantageous, because it better mimics the normal insulin pathway after endogenous secretion (Hoffman and Ziv, 1997, Owens, 2002). However, insulin, as other polypeptides, presents formulation challenges such as poor chemical and physical stability and short plasma half-time. This often leads to low bioavailability, mainly resulting from degradation in the stomach, digestion and inactivation in the intestinal cavity by proteolytic enzymes, and poor permeability through the intestinal epithelium because of its lack of lipophilicity and high molecular weight (Carino and Mathiowitz, 1999).
Solid lipid nanoparticles (SLN) are submicron colloidal carriers (usually 50–1000 nm), composed of lipids that are solid at body and room temperature, and dispersed either in an aqueous surfactant solution or water (Rawat et al., 2006). The lipids that compose SLN can be complex acylglycerol mixtures, highly purified triacylglycerols or waxes. SLN gained increased interest among nanoparticulate systems in the past years mainly due to their biocompatibility, good tolerability, biodegradation (Almeida and Souto, 2007, Sarmento et al., 2007b), and even by the possibility of large industrial scale production (Muller et al., 2000). It has been reported that lipid nanoparticles encapsulating therapeutic proteins can improve their bioavailability, prolong their blood residence time, and/or modify their biodistribution (Garcia-Fuentes et al., 2005). In fact, SLN are able to protect proteins from enzymatic degradation in the intestinal environment and enhance their selective uptake, resulting in prolonged therapeutic effect (Sarmento et al., 2007b). Therefore, SLN have been proposed for the oral delivery of insulin for the treatment of diabetes mellitus (Liu et al., 2007, Sarmento et al., 2007b, Trotta et al., 2005, Zhang et al., 2006). Actually, SLN and other lipid-based drug delivery systems are known to enhance the oral absorption of many drugs (Charman, 2000, Charman et al., 1997). When SLN are administered orally, they can be absorbed either through the membranous epithelial cells (M-cells) of the Peyer's patches in the gut-associated lymphoid tissue (GALT) or transcellularly (Damge et al., 2008).
Surface modification of nanoparticles with chitosan, a natural cationic polysaccharide derived from chitin, is a promising strategy to enhance the penetration of encapsulated macromolecules, such as insulin, through mucosal surfaces. This biopolymer has been used for developing drug delivery systems because of its good biocompatibility, biodegradability, low toxicity, antimicrobial, mucoadhesive, and absorption enhancing properties (Braz et al., 2011). Insulin-loaded chitosan nanoparticles have been shown to yield a significant hypoglycemic effect when administered orally to diabetic animal models (Cui et al., 2009, Reis et al., 2008, Sarmento et al., 2007c, Sarmento et al., 2007d). In fact, the mucoadhesive properties of chitosan may enhance drug uptake, because the contact with the intestinal epithelium is maintained for longer periods and the penetration of the active drug is improved because of the prolonged concentration gradient between the intestinal membrane and nanoparticles. Further, chitosan is an effective permeability enhancer as it reversibly changes tight junctions (Cano-Cebrian et al., 2005, Smith et al., 2005).
Recently, our group demonstrated the ability of chitosan-coated SLN to enhance the intestinal uptake of insulin by showing its physiologic effect after oral administration to rats (Fonte et al., 2011). Comparatively to uncoated SLN, we were able to reach a significant improvement of the hypoglycemic effect. This is probably due to chitosan mucoadhesive properties which promote the intestinal insulin uptake while overcoming the degradation of insulin in the gastrointestinal tract. Nevertheless, there is a major limitation in the oral delivery of insulin-loaded nanoparticles, besides the rate of permeation of nanoparticles through the intestinal epithelium, which is the elimination of nanoparticles by the mononuclear phagocyte system (MPS) (Champion et al., 2008, Yin et al., 2007). Macrophages present in tissues such as the lymph nodes, liver, spleen, and bone marrow are also an additional factor in the elimination of nanoparticles. The role of PEG (Owens and Peppas, 2006) and some hydrophilic polysaccharide (Lemarchand et al., 2004) coating in avoiding phagocytosis of nanoparticles by macrophages is reported in the literature. Recently, we have demonstrated that chitosan-coated SLN were not internalized by the murine macrophage cell line, RAW 264.7, while uncoated SLN were taken up by these cells (Sarmento et al., 2011). Chitosan was able to provide stealth properties to SLN, resulting in the absence of phagocytosis. All these findings open perspectives for the optimization of long-time blood circulating chitosan nanoparticles.
Section snippets
Preparation of Chitosan-Coated SLN
The described method for the preparation of chitosan-coated SLN is based on those developed previously by our group for the delivery of insulin (Fonte et al., 2011, Sarmento et al., 2011). It is based on the initial preparation of negatively charged SLN by a water-in-oil-in-water (w/o/w) emulsion method, followed by their coating with low molecular weight chitosan. The coating mechanism of SLN is simple adsorption resulting from the electrostatic interaction of chitosan (positively charged)
Determination of particle size and polydispersity index
The measurement of particle size is generally performed using photon correlation spectroscopy (PCS) also called quasi-elastic light scattering (QELS) or dynamic light scattering (DLS), which is based on the scattering of a laser light by submicron particles in suspension in a time-dependent manner (Xu, 2002b). The diffusion of particles over time (Brownian motion) causes fluctuations in the intensity of the light scattered at a certain detection angle (varying from 10° to 90°). The technique is
Insulin bioactivity
The maintenance of the biological activity of insulin after encapsulation can be assessed by a commercially available enzyme-linked immunosorbent assay (ELISA) (Mercodia, Uppsala, Sweden). This ELISA kit comprises a solid phase two-site enzyme immunoassay. It is based on the direct sandwich technique in which two monoclonal antibodies are directed against separate antigenic determinants of the insulin molecule. During incubation, the insulin in the sample reacts with peroxidase-conjugated
Acknowledgments
This work was supported by Fundação para a Ciência e a Tecnologia, Portugal (PTDC/SAU-FCF/104492/2008, SFRH/BPD/35996/2007, and PTDC/SAU-FCF/70651/2006).
References (39)
- et al.
Solid lipid nanoparticles as a drug delivery system for peptides and proteins
Adv. Drug Deliv. Rev.
(2007) - et al.
Oral insulin delivery
Adv. Drug Deliv. Rev.
(1999) Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts
J. Pharm. Sci.
(2000)- et al.
Physiochemical and physiological mechanisms for the effects of food on drug absorption: The role of lipids and pH
J. Pharm. Sci.
(1997) - et al.
New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin
Int. J. Pharm.
(2005) - et al.
Qualification of FTIR spectroscopic method for protein secondary structural analysis
J. Pharm. Sci.
(2011) - et al.
Polysaccharide-decorated nanoparticles
Eur. J. Pharm. Biopharm.
(2004) - et al.
Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: Preparation and characterization
Int. J. Pharm.
(2007) - et al.
Solid lipid nanoparticles (SLN) for controlled drug delivery—A review of the state of the art
Eur. J. Pharm. Biopharm.
(2000) - et al.
Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles
Int. J. Pharm.
(2006)
Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response
J. Pharm. Sci.
Development and characterization of new insulin containing polysaccharide nanoparticles
Colloids Surf. B Biointerfaces
Probing insulin's secondary structure after entrapment into alginate/chitosan nanoparticles
Eur. J. Pharm. Biopharm.
Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system
Carbohydr. Polym.
Involvement of protein kinase C in chitosan glutamate-mediated tight junction disruption
Biomaterials
Solid lipid micro-particles carrying insulin formed by solvent-in-water emulsion-diffusion technique
Int. J. Pharm.
Lectin-conjugated PLGA nanoparticles loaded with thymopentin: Ex vivo bioadhesion and in vivo biodistribution
J. Control. Release
Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery
Biomaterials
Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin
Int. J. Pharm.
Cited by (93)
An apprise on novel drug delivery systems for management of diabetes mellitus
2024, Journal of Drug Delivery Science and TechnologyNanoparticle oral absorption and its clinical translational potential
2023, Journal of Controlled ReleaseIn vitro physicochemical characterization of nanocarriers: a road to optimization
2022, Nanoparticle Therapeutics: Production Technologies, Types of Nanoparticles, and Regulatory AspectsFlower-like biogenic gold nanostructures for improved catalytic reduction of 4-nitrophenol
2021, Journal of Environmental Chemical EngineeringNovel biogenic gold nanoparticles catalyzing multienzyme cascade reaction: Glucose oxidase and peroxidase mimicking activity
2021, Chemical Engineering Journal